1. Home
  2. GLPG

GLPG

Galapagos NV

Logo Galapagos NV

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-19-2024 3:31pm EST

$
-
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing medicines. The company is committed to improving patients' lives world-wide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. It derives maximum revenue from United States of America.

Founded: 1999 Country:
Belgium
Belgium
Employees: N/A City: N/A
Market Cap: 1.9B IPO Year: 2005
Target Price: $43.80 AVG Volume (30 days): 125.5K
Analyst Decision: Hold Number of Analysts: 5
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: 3.42 EPS Growth: N/A
52 Week Low/High: $30.24 - $45.21 Next Earning Date: 05-02-2024
Revenue: $266,360,000 Revenue Growth: N/A
Revenue Growth (this year): 76.06% Revenue Growth (next year): -14.12%

Share on Social Networks: